I80.2
Conditions
Interventions
Group 1: Study group of adult patients (= 18 years, n=500) presenting to the Central Emergency Department at Campus Benjamin Franklin - Charité, Universitätsmedizin Berlin, who have a clinical disposi
parameters of thrombin formation, thrombogenicity, inflammation (Prothrombin Fragment F1.2., Thrombin-Antithrombin Complex (TATcomplex), D-Dimer, Plasmin-alpha2-Antiplasmin Complex (PAPcomplex), Tissu
Sponsors
Charité, Universitätmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria Study group: - Patients aged =18 years who have been informed verbally and in writing about participation in the study and have signed the informed consent form. - Patients presenting via the Central Emergency Department at Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin - Patients who, according to the latest AWMF-S3 guideline: Prophylaxis of venous thromboembolism (VTE), have a low, medium or high clinical dispositional and/or exposure risk for VTE (see eCRF, AWMF-S3 guideline: Prophylaxis of venous thromboembolism (VTE)). Inclusion criteria Control group: - Patients aged =18 years who have been informed verbally and in writing about participation in the study and have signed the informed consent form. - Patients presenting via the Central Emergency Department at Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin - Patients who, according to the current AWMF-S3 guideline: Prophylaxis of venous thromboembolism (VTE), have no clinical risk of VTE (see eCRF, AWMF-S3 guideline: Prophylaxis of venous thromboembolism (VTE)).
Exclusion criteria
Exclusion criteria: - Refusal to participate in the study or declaration of unwillingness to participate in the study. - Patients not able to give consent. - Participation in this study in the past. - Underage patients. - Transfusion within the last 3 months. - Erythropoietin therapy within the last 3 months. - Patients who are currently enrolled in another study that involves blood sampling with more than 35 ml of blood per week.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Comparison of the proportion of PS-positive erythrocytes in patients with and without clinical risk of VTE. - Correlation of the proportion of PS positive red cells with parameters of thrombin information, thrombogenicity and inflammation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive value (positive and negative predictive value) of PS expression on erythrocyte membranes in relation to: - Identification of VTE. - Clinical VTE scores (Wells Score TVT/LE, Geneva Score (revised) for PE, Caprini Score, Padua Prediction Score for Risk of VTE, Geneva Risk Score for VTE Prophylaxis, Ottawa Score, PERC-Rule, YEARS Algorithm for PE, Khorana Score). - VTE-associated or therapy-associated complications (bleeding, arrhythmias, infections, ischemia, stroke, death). - Initiation of anticoagulation. - “All-cause” mortality. - Need for inpatient therapy. - Duration of inpatient therapy. - Need for intensive care therapy. | — |
Countries
Germany
Contacts
Public ContactFabian Depré
Charité, Universitätsmedizin Berlin
Outcome results
None listed